News | August 13, 2025
Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
The closing of the Block Acquisition is now expected to be completed by Q3 2025
ANVIMO will be available in dosages of 240 mg and 480 mg
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
Zydus Lifesciences and SBL have mutually decided to extend the date of closing upto March 31, 2025
Subscribe To Our Newsletter & Stay Updated
